EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization

Yixuan Zhao, Rachael Liu, Jianchang Lin, Ying Yuan iD

Clinical Trials · 2025

DOI: 10.1177/17407745251350596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Yixuan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Maximum Tolerated Dose. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute, national cancer institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One common approach for dose optimization is a two-stage design, which initially conducts dose escalation to identify the maximum tolerated dose, followed by a randomization stage where patients are assigned to two or more doses to further assess and compare their risk-benefit profiles to identify the optimal dose. A limitation of this approach is its requirement for a relatively large sample size. To address this challenge, we propose a seamless two-stage design, BARD (Backfill and Adaptive Randomization for Dose Optimization), which incorporates two key features to reduce sample size and shorten trial duration. The first feature is the integration of backfilling into the stage 1 dose escalation, enhancing patient enrollment and data generation without prolonging the trial. The second feature involves seamlessly combining patients treated in stage 1 with those in stage 2, enabled by covariate-adaptive randomization, to inform the optimal dose and thereby reduce the sample size. Our simulation study demonstrates that BARD reduces the sample size, improves the accuracy of identifying the optimal dose, and maintains covariate balance in randomization, allowing for unbiased comparisons between doses. BARD designs offer an efficient solution to meet the dose optimization requirements set by Project Optimus, with software freely available at www.trialdesign.org.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignRandomized Controlled Trials as TopicMaximum Tolerated DoseHumansSample SizeDose-Response Relationship, DrugComputer Simulation

Stichwörter der Autor:innen

Dose optimizationProject Optimusadaptive designsdose findingseamless designs

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Biostatistics, Takeda Pharmaceuticals, Boston, MA, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Ying Yuan

Förderung

  • NCI NIH HHS
  • Division of Cancer Prevention, National Cancer Institute
  • national cancer institute

Zitieren

APA

Zhao, Y., Liu, R., Lin, J., & Yuan, Y. (2025). BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization. Clinical Trials. https://doi.org/10.1177/17407745251350596

Vancouver

Zhao Y, Liu R, Lin J, Yuan Y. BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization. Clinical Trials. 2025. doi:10.1177/17407745251350596

BibTeX
@article{Zhao2025,
  author = {Zhao, Yixuan and Liu, Rachael and Lin, Jianchang and Yuan, Ying},
  title = {BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization},
  journal = {Clinical Trials},
  year = {2025},
  doi = {10.1177/17407745251350596}
}
Kostenlos starten →